Market Closed -
Bombay S.E.
11:00:53 01/07/2024 BST
|
5-day change
|
1st Jan Change
|
22.76
INR
|
-1.81%
|
|
-1.26%
|
-24.03%
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,061
|
508.7
|
1,106
|
2,432
|
1,700
|
929.4
|
Enterprise Value (EV)
1 |
3,123
|
1,350
|
1,565
|
2,588
|
1,730
|
1,125
|
P/E ratio
|
16.6
x
|
-4.23
x
|
30.6
x
|
10.7
x
|
-31.7
x
|
-2.41
x
|
Yield
|
-
|
-
|
-
|
0.42%
|
0.6%
|
-
|
Capitalization / Revenue
|
0.85
x
|
0.3
x
|
0.66
x
|
1.2
x
|
1.24
x
|
0.72
x
|
EV / Revenue
|
1.28
x
|
0.8
x
|
0.94
x
|
1.28
x
|
1.26
x
|
0.87
x
|
EV / EBITDA
|
7.57
x
|
11.9
x
|
4.75
x
|
5.48
x
|
10.5
x
|
-24
x
|
EV / FCF
|
-13.3
x
|
5.02
x
|
21.1
x
|
12.9
x
|
7.52
x
|
7.99
x
|
FCF Yield
|
-7.51%
|
19.9%
|
4.73%
|
7.76%
|
13.3%
|
12.5%
|
Price to Book
|
1.76
x
|
0.48
x
|
0.78
x
|
1.53
x
|
1.14
x
|
0.79
x
|
Nbr of stocks (in thousands)
|
22,864
|
22,864
|
40,673
|
40,673
|
40,673
|
50,101
|
Reference price
2 |
90.15
|
22.25
|
27.20
|
59.80
|
41.80
|
18.55
|
Announcement Date
|
06/09/18
|
06/09/19
|
03/09/20
|
01/09/21
|
02/09/22
|
04/09/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,435
|
1,696
|
1,673
|
2,024
|
1,371
|
1,296
|
EBITDA
1 |
412.6
|
113.5
|
329.2
|
472.7
|
164.7
|
-46.8
|
EBIT
1 |
231
|
-79.56
|
155.8
|
314.4
|
24.72
|
-181
|
Operating Margin
|
9.48%
|
-4.69%
|
9.32%
|
15.54%
|
1.8%
|
-13.97%
|
Earnings before Tax (EBT)
1 |
152.3
|
-161
|
47.36
|
294.9
|
-62.1
|
-422.7
|
Net income
1 |
123.4
|
-120.3
|
36.28
|
227.8
|
-53.67
|
-386.2
|
Net margin
|
5.07%
|
-7.09%
|
2.17%
|
11.25%
|
-3.91%
|
-29.81%
|
EPS
2 |
5.429
|
-5.262
|
0.8900
|
5.600
|
-1.320
|
-7.710
|
Free Cash Flow
1 |
-234.5
|
269
|
74.08
|
200.8
|
230.2
|
140.8
|
FCF margin
|
-9.63%
|
15.86%
|
4.43%
|
9.92%
|
16.79%
|
10.87%
|
FCF Conversion (EBITDA)
|
-
|
236.94%
|
22.5%
|
42.49%
|
139.76%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
204.16%
|
88.17%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.2500
|
0.2500
|
-
|
Announcement Date
|
06/09/18
|
06/09/19
|
03/09/20
|
01/09/21
|
02/09/22
|
04/09/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1,062
|
842
|
458
|
156
|
29.8
|
196
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.573
x
|
7.415
x
|
1.393
x
|
0.3306
x
|
0.1809
x
|
-4.187
x
|
Free Cash Flow
1 |
-234
|
269
|
74.1
|
201
|
230
|
141
|
ROE (net income / shareholders' equity)
|
12.8%
|
-10.8%
|
2.94%
|
15.2%
|
-3.49%
|
-28%
|
ROA (Net income/ Total Assets)
|
5.61%
|
-1.82%
|
3.97%
|
8.94%
|
0.76%
|
-6.06%
|
Assets
1 |
2,201
|
6,596
|
913.7
|
2,549
|
-7,072
|
6,368
|
Book Value Per Share
2 |
51.30
|
46.10
|
34.80
|
39.10
|
36.50
|
23.60
|
Cash Flow per Share
2 |
0.2200
|
0.1800
|
0.6300
|
0.9400
|
2.710
|
0.4300
|
Capex
1 |
467
|
113
|
6.27
|
65.9
|
-
|
-
|
Capex / Sales
|
19.18%
|
6.68%
|
0.37%
|
3.25%
|
-
|
-
|
Announcement Date
|
06/09/18
|
06/09/19
|
03/09/20
|
01/09/21
|
02/09/22
|
04/09/23
|
|
1st Jan change
|
Capi.
|
---|
| -12.56% | 79.1B | | -5.37% | 7.13B | | +25.38% | 3.58B | | -6.12% | 2.93B | | +14.19% | 1.69B | | -7.71% | 1.19B | | -32.50% | 1.11B | | -35.50% | 1.05B | | -28.56% | 939M |
Veterinary Drugs
|